Diligence memo · auto-generated · as of July 2, 2026
Argon AI, Inc.
Argon AI, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Argon AI, Inc. operates in Pharma, based in BROOKLYN, NY, USA. AI for Pharma Intelligence
Sub-sector tags: ai/ml, data/analytics, pharma.
Capital & rounds (filed)filed
Argon AI, Inc. has raised $5.5M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.5M on 2024-05-31.
Most recent recorded round closed around 2024-05-31.
Valuation (modeled)modeled
Provath models Argon AI, Inc. at approximately $30M (range $6.3M–$65M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.43× the median modeled value of Series A Pharma companies in 2022–2024 (24 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 2.1 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 56% of Pharma peers (310 compared).
Modeled value ranks above 48% of those peers.
Closest niche peers: Carmine Therapeutics, Inc., Triomics, Inc., Spiral Therapeutics Inc, Convelo Therapeutics, Inc., ADvantage Therapeutics, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.